Clinical Effect of Sijunzi Decoction Combined with rhG-CSF on Leukopenia Caused by Postoperative Chemotherapy in Ovarian Cancer Patients
Objective To analyze the clinical effect of Sijunzi decoction combined with recombinant human granulocyte stimulating factor injection(rhG-CSF)on leukopenia caused by postoperative chemotherapy in ovarian cancer patients.Methods A total of 80 patients with leukopenia caused by chemotherapy for ovarian cancer were randomly divided into the control group(40 cases)and the combined group(40 cases).Among them,the control group was treated with rhG-CSF,and the combined group was given Sijunzi decoction combined with rhG-CSF.Compared the levels of Th1 cytokines in the 2 groups[tumor necrosis factor α(TNF-α),γ-interferon(IFN-γ),interleukin-2(IL-2)],Th2 cytokine levels[interleukin-6(IL-6),interleukin-4(IL-4),interleu-kin-10(IL-10)],white blood cell count(WBC),platelet count(PLT),neutrophil count(NE),TCM syndrome points,Clinical effi-cacy and occurrence of adverse reactions.Results Compared with the pre-treatment period,serum TNF-α,IL-6,IL-4,IL-10 lev-els,fatigue,self-sweating night sweats,lack of food,and waist and knee soreness were significantly reduced(P<0.05)after treat-ment,and compared with the control group,the observation group significantly decreased(P<0.05).The serum levels of IFN-γ,IL-2,WBC,PLT,and NE in the 2 groups were significantly increased(P<0.05),and compared with the control group,the obser-vation group was significantly elevated(P<0.05).The total effective rate of the observation group(52.50%)was significantly higher than that of the control group(30.00%)(P<0.05).The incidence of adverse reactions in the observation group(2.50%)was significantly lower than that in the control group(20.00%)(P<0.05).Conclusion Sijunzi decoction combined with rhG-CSF in the treatment of patients with leukopenia caused by chemotherapy after ovarian cancer can effectively improve clinical symptoms,increase leukocyte levels,and improve immune function,which is safe and effective.
LeukopeniaOvarian cancerRecombinant human granulocyte stimulating factor injectionSecurityEfficacy
万方数据
维普
